Company news

NervGen Pharma Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

October 12, 2026

NervGen Pharma Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

October 12, 2026

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

September 25, 2026

NervGen to Host Inaugural R&D Day on September 30, 2026

September 9, 2026

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

May 26, 2026

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

May 21, 2026

NervGen Announces Proposed Public Offering of Securities

May 21, 2026

NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

May 18, 2026

NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer

April 27, 2026

NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference

April 13, 2026

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia

April 6, 2026

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

March 30, 2026

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

March 11, 2026

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

March 3, 2026

NervGen Pharma to Participate at Upcoming Investor Conferences

February 18, 2026

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

February 11, 2026

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

February 11, 2026

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

February 8, 2026

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

January 20, 2026

Decks

The 5 newest of 33 decks. Every deck is listed under its year.